Atrial Fibrillation Monitoring on Patients With Lymphoma After Chemotherapy

Atrial Fibrillation Clinical Trial

Official title:

A Cohort Study of Atrial Fibrillation Monitoring on Patients With Lymphoma After Chemotherapy by Applying Wearable Electrocardiogram

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05454878
• Other study ID #: LAF-20220523
• Status: Not yet recruiting
• Start date: July 15, 2022
• Est. completion date: December 1, 2023

Study information

• Verified date: June 2022
• Source: Chinese PLA General Hospital
• Contact: Yundai Chen
• Phone: +86 01055499135
• Email: cyundai[@]vip.163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This prospective cohort study is to investigate the incidence of atrial fibrillation after chemotherapy by aplying wearable ECG recoder and the risk factors on patients with newly diagonsed lymphoma

Description:

This prospective, single-centre, observational cohort study is disigned to enroll 100 newly diagnosed lymphoma patients who met the inclusion and exclusion criteria to monitor the onset of atrial fibrillation and other arrhythmias during chemotherapy by using wearable ECG recorder, and to evaluate the incidence of atrial fibrillation and related risk factors.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 100
• Est. completion date: December 1, 2023
• Est. primary completion date: July 1, 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. At least 18 years old;

2. Concurrent chemotherapy on patients with new-onset lymphoma: chemotherapy regimens containing anthracyclines;

3. The subject voluntarily signed the informed consent.

Exclusion Criteria:

1. With heart failure, acute stroke or acute coronary syndrome within 3 months before admission

2. With Atrial fibrillation on admission

3. Patient after pacemaker surgery

4. With mental illness or mentally disabled

5. Patients that the investigator considers as unsuitable for this test

Related Conditions & MeSH terms

• Atrial Fibrillation
• Lymphoma

Locations

Country	Name	City	State
China	General hospital of PLA	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese PLA General Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence	Incidence of atrial fibrillation after chemotherapy	1 year after the first course of chemotherapy